Free Newsletter
GSK confident it can prevail in vaccine battle
GSK's battle to win over the $2 billion market for cervical cancer vaccines has experienced a few big setbacks. French health officials are now recommending against paying for Cervarix and the FDA has lingered long over GSK's application for approval. But Glaxo U.S. pharma chief Chris Viehbacher (photo) insists in a talk with the Wall Street Journal that all is well. Viehbacher says that at the end of the day, head-to-head study data will prove too compelling for the regulators on both sides of the Atlantic to ignore. Meanwhile, though, Merck's Gardasil continues to solidify its position in the market.
- read the report in the Wall Street Journal
Related Articles:
GSK hit with Cervarix application delay
It's Merck v. Glaxo in vaccine battle
GSK prepares to go head-to-head with Merck
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
